The treatment of multiple myeloma (MM) is evolving rapidly. In recent years, T-cell-based novel immunotherapies emerged as new treatment strategies for patients with relapsed/refractory MM, including highly effective new options like chimeric antigen receptor (CAR)-modified T cells and bispecific antibodies (bsAbs). Currently, B-cell maturation antigen is the most commonly used target antigen for CAR T-cell and bsAb therapies in MM. Results from different clinical trials have demonstrated promising efficacy and acceptable safety profile of bsAb in RRMM.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.hoc.2023.12.003 | DOI Listing |
Publication Analysis
Top Keywords
bispecific antibodies
8
treatment multiple
8
multiple myeloma
8
antibodies treatment
4
myeloma treatment
4
myeloma evolving
4
evolving rapidly
4
rapidly years
4
years t-cell-based
4
t-cell-based novel
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!